Hydromorphone
(Dilaudid®) is marketed in tablets (2, 4,
and 8 mg), rectal Suppositories, oral solutions,
and injectable formulations. All products are
in Schedule II of the CSA. Its analgesic potency
is from two to eight times that of morphine, but
it is shorter acting and produces more sedation
than morphine. Much sought after by narcotic addicts,
hydromorphone is usually obtained by the abuser
through fraudulent prescriptions or theft. The
tablets are often dissolved and injected as a
substitute for heroin.
Source: DEA
|
